SAN DIEGO--(BUSINESS WIRE)--Vividion Therapeutics, a biotechnology company discovering and developing selective small molecule medicines that drug traditionally inaccessible targets, today announced that Jeffrey Hatfield has been appointed as the company’s chief executive officer. Mr. Hatfield brings more than 35 years of successful industry leadership to Vividion, having held multiple senior executive, CEO and board director roles during his career at both Fortune 500 pharmaceutical and emerging biotechnology companies.
“Jeff is a highly accomplished industry leader who can help us deliver the full potential of Vividion’s differentiated discovery platform,” said Richard Heyman, Ph.D., chairman of the Vividion board of directors. “Jeff brings decades of relevant experience, including building platform-based companies, advancing first-in-class programs, executing financing strategies to drive near and long-term value growth, negotiating innovative business development partnerships and strategic transactions, and cultivating collaborative, high-performance cultures. The board is confident in Jeff’s ability to drive significant future growth, and we are thrilled to welcome him to the team.”
“Vividion is built on unprecedented insights into emerging and synergistic technologies, which together, create a powerful drug discovery platform with the potential to tremendously expand horizons for small molecule discovery – beyond what we consider possible today,” said Mr. Hatfield. “The company stands well positioned for success, with several rapidly advancing first-in-class programs in oncology and immunology, major pharmaceutical collaborations with BMS and Roche, a multi-year cash runway, and the significant backing of top-tier life science investors. I am excited to join this highly talented team as we work together to bring forward important new medicines that have the opportunity to extend and enhance the lives of millions of patients around the world.”
Among Mr. Hatfield’s many career leadership roles, he previously served as the CEO of Vitae Pharmaceuticals, Inc., a pioneer in computational structure-based drug discovery, where he led the company from start-up to clinical-stage advancement of multiple first-in-class programs, and ultimately to its $640 million acquisition by Allergan Plc. Earlier, he served as a senior executive at Bristol-Myers Squibb (BMS), where he held roles including senior vice president, Immunology and Virology Divisions; president, BMS-Canada; and head of U.S. market access. Mr. Hatfield currently serves as chairman of the board of miRagen Therapeutics, Inc. and as a board member at aTyr Pharma. He also serves as a Key Advisory Board member for the Harvard Business School’s Blavatnik Fellowship in Life Science Entrepreneurship, and is a faculty member at Purdue University, where he teaches entrepreneurship to doctoral students. Mr. Hatfield holds an MBA from The Wharton School, University of Pennsylvania, and a B.S. from the Purdue University College of Pharmacy.
Vividion Therapeutics, Inc. is a biotechnology company focused on transforming the future of human health through the creation of highly selective small molecule medicines that drug traditionally inaccessible targets. The company is advancing a broad, diversified pipeline of multiple, selective small molecule therapeutics for highly sought-after disease-causing target proteins in oncology and immunology. For more information, please visit www.vividion.com.